HBV相关慢加急性肝衰竭前期概念及诊疗新进展*

doi:10.3969/j.issn.1672-5069.2015.01.030

摘要/Abstract

摘要： HBV相关慢加急性肝衰竭（ACLF）严重影响人类健康。该病病情进展较快、病死率高。如果能在患者发生ACLF之前,及时将其筛选并获得诊断,进行必要的干预和治疗,将对患者预后产生重要的影响。因此,一些学者开始重视对肝衰竭前期患者的研究。由于对疾病定义存在差异,国外和我国香港、台湾地区学者将慢性乙型肝炎严重急性发作定义为肝衰竭前期,而我国大陆也有学者尝试着制定了三种不同的慢加急性肝衰竭前期诊断标准。本文主要就ACLF前期概念及诊疗进展进行讨论。

关键词: 乙型肝炎, 肝衰竭, 前期, 诊断, 治疗

Abstract: Hepatitis B virus （HBV）-related acute-on-chronic liver failure （ACLF）,characterized by rapid disease progression and high mortality,is a serious health problem in China. The outcomes will differ if the clinicians can diagnose the patients with ACLF in time and give them instant intervention. So some scholars in the world began to study the patients in so-called pre-liver failure stage. The scholars in the west,Hong Kong and Taiwan defined it as severe acute exacerbation of chronic hepatitis B,while the scholars in the mainland tried to set up three different diagnostic criteria for pre-ACLF. This review mainly focuses on recent advances in the definition, diagnosis and treatment of patients with HBV-related pre-ACLF.

Key words: Hepatitis B, Liver failure, Pre-stage, Diagnosis, Treatment

李晨, 游绍莉, 辛绍杰. HBV相关慢加急性肝衰竭前期概念及诊疗新进展^*[J]. 实用肝脏病杂志, 2015, 18(1): 105-108.

Li Chen, You Shaoli, Xin Shaojie. What's new The definition,diagnosis and management of HBV-related pre- acute-on-chronic liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 105-108.

参考文献

[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[2] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of chronic hepatitis B virus infection. J Hepatol,2012,57（1）:167-185.
[3] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南.实用肝脏病杂志,2013,16（3）：210-216.
[4] Sarin SK,Kumar A,Almeida JA,et al. Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the study of the liver （APASL）. Hepatol Int,2009,3（1）:269-282.
[5] Moreau R,Jalan R,Gines P,et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology,2013,144（7）:1426-1437.
[6] Yu S,Jianqin H,Wei W,et al. The efficacy and safety of nucleos（t）ide analogues in the treatment of HBV-related acute-on-chronic liver failure:a meta-analysis. Ann Hepatol,2013,12（3）:364-372.
[7] Zheng Z,Li X,Li Z,et al. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure:A meta-analysis and meta-regression. Exp Ther Med,2013,6（4）:929-936.
[8] Xu X,Liu X,Ling Q,et al. Artificial liver support system combined with liver transplantation in the treatment of patients with acute-on-chronic liver failure. PLoS One,2013,8（3）:e58738.
[9] 杨晓鲲,徐贵森. 糖皮质激素治疗乙型肝炎病毒相关性肝衰竭疗效的Meta分析. 解放军医学杂志,2013,38（7）:581-585.
[10] Kamath PS,Wiesner RH,Malinchoc M,et al. A model to predict survival in patients with end-stage liver disease. Hepatology,2001,33（2）:464-470.
[11] Biggins SW,KimWR,TerraultNA,et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology,2006,130（6）:1652-1660.
[12] Luca A,Angermayr B,Bertolini G,et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl,2007,13（8）:1174-1180.
[13] 林贤丰,李凌菲,俞燮琰,等. MELD相关评分体系对乙型肝炎相关慢加急性肝衰竭患者预后的预测价值. 中华临床医师杂志（电子版）,2012,6（19）: 5853-5857.
[14] 李晨,游绍莉,刘鸿凌,等.基线MELD、MELD-Na、iMELD3种模型对乙型肝炎病毒相关慢加急性肝衰竭患者近期预后的评估价值.中华危重病急救医学,2014, 26（8）:6-10.
[15] 骆欣,朱国献,刘惠敏,等.753例重型肝炎病原学及预后相关因素分析. 医学研究杂志,2011,40（2）:96-98.
[16] 汤伟亮,赵钢德,董志霞,等. 肝衰竭预后危险因素及预后模型建立的研究. 传染病信息,2011,24（3）:159-162.
[17] Garg H,Kumar A,Garg V,et al. Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute-on-chronic liver failure. J Gastroenterol Hepatol,2013,28（8）:1361-1367.
[18] Wong VW,Chan HL. Severe acute exacerbation of chronic hepatitis B:a unique presentation of a common disease. J Gastroenterol Hepatol,2009,24（7）:1179-1186.
[19] Chien RN,Lin CH,Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol,2003,38（3）:322-327.
[20] Chan HL,Tsang SW,Hui Y,et al. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat,2002,9（6）:424-428.
[21] Yuen MF,Sablon E,Hui CK,et al. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis,2003,36（8）:979-984.
[22] Tsubota A,Arase Y,Suzuki Y,et al. Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection. Intervirology,2004,47（6）:335-341.
[23] Mao Q,Zhang HY,You JP,et al. Severe acute exacerbation of chronic hepatitis B during pegylated interferon treatment and early intervention with corticosteroid. Virol J,2012,9:136.
[24] Fujiwara K,Yasui S,Okitsu K,et al. The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Gastroenterol,2010,45（12）:1255-1262.
[25] Fujiwara K,Yasui S,Yonemitsu Y,et al. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol,2008,43（9）:711-719.
[26] Tsubota A,Arase Y,Suzuki Y,et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol,2005,20（3）:426-432.
[27] Chien RN,Lin CH,Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol,2003,38（3）:322-327.
[28] Chan HL,Wong VW,Hui AY,et al. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antivir Ther,2006,11（4）:465-471.
[29] Wong VW,Wong GL,Tsang SW,et al. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen （HBeAg）-positive chronic hepatitis B. Antivir Ther,2008,13（4）:571-579.
[30] Wong VW,Wong GL,Yiu KK,et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol,2011,54（2）:236-242.
[31] Tsai WL,Chiang PH,Chan HH,et al. Early entecavir treatment for chronic hepatitis B with severe acute exacerbation. Antimicrob Agents Chemother,2014,58（4）:1918-1921.
[32] Chen CH,Lin CL,Hu TH,et al. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol,2014,60（6）:1127-1134.
[33] 刘明,张绪清,毛青. 慢加急性肝衰竭前期的概念及预警模型. 临床肝胆病杂志,2012,28（10）:732-734.
[34] 刘明,邓国宏,谭顺,等. 慢加急性肝衰竭前期临床常规预警指标研究. 第三军医大学学报,2012,34（8）:772-775.
[35] Zhang XQ,Jiang L,You JP,et al. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res,2011,41（1）:46-53.
[36] Xia Q, Dai X,Zhang Y,et al. A modified MELD model for Chinese pre-ACLF and ACLF patients and it reveals poor prognosis in pre-ACLF patients. PLoS One,2013,8（6）:e64379.

HBV相关慢加急性肝衰竭前期概念及诊疗新进展^*

What's new The definition,diagnosis and management of HBV-related pre- acute-on-chronic liver failure

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[5]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[6]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[7]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[8]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[9]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[10]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[11]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[12]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[13]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[14]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[15]	曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903.